Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Protein kinase Mζ is necessary and sufficient for LTP maintenance

Nature Neuroscience volume 5, pages 295–296 (2002)Cite this article

Abstract

Long-term potentiation (LTP), a persistent synaptic enhancement thought to be a substrate for memory1, can be divided into two phases: induction, triggering potentiation, and maintenance, sustaining it over time1,2. Many postsynaptic events are implicated in induction, including N-methyl-D-aspartate receptor (NMDAR) activation, calcium increases and stimulation of several protein kinases1; in contrast, the mechanism maintaining LTP is not yet characterized1. Here we show the constitutively active form of an atypical protein kinase C (PKC) isozyme, protein kinase M zeta (PKMζ), is necessary and sufficient for LTP maintenance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Postsynaptic diffusion of PKMζ enhanced evoked EPSC amplitudes.
Figure 2: Potentiation by PKMζ occluded LTP and inhibition by PKMζ-K281W blocked LTP.
Figure 3: Persistent phosphorylation by PKMζ is necessary for LTP maintenance.

Similar content being viewed by others

References

  1. Malenka, R. C. & Nicoll, R. A. Science 285, 1870–1874 (1999).

    Article  CAS  Google Scholar 

  2. Malinow, R., Madison, D. V. & Tsien, R. W. Nature 335, 820–824 (1988).

    Article  CAS  Google Scholar 

  3. Schwartz, J. H. & Greenberg, S. M. Annu. Rev. Neurosci. 10, 459–476 (1987).

    Article  CAS  Google Scholar 

  4. Nishizuka, Y. FASEB J. 9, 484–496 (1995).

    Article  CAS  Google Scholar 

  5. Otmakhov, N., Griffith, L. C. & Lisman, J. E. J. Neurosci. 17, 5357–5365 (1997).

    Article  CAS  Google Scholar 

  6. Denny, J. B., Polan-Curtain, J., Rodriguez, S., Wayner, M. J. & Armstrong, D. L. Brain Res. 534, 201–208 (1990).

    Article  CAS  Google Scholar 

  7. Sacktor, T. C. et al. Proc. Natl. Acad. Sci. USA 90, 8342–8346 (1993).

    Article  CAS  Google Scholar 

  8. Lledo, P. M. et al. Proc. Natl. Acad. Sci. USA 92, 11175–11179 (1995).

    Article  CAS  Google Scholar 

  9. Lallena, M. J., Diaz-Meco, M. T., Bren, G., Paya, C. V. & Moscat, J. Mol. Cell. Biol. 19, 2180–2188 (1999).

    Article  CAS  Google Scholar 

  10. McGlynn, E. et al. J. Cell. Biochem. 49, 239–250 (1992).

    Article  CAS  Google Scholar 

  11. Thompson, L. J. & Fields, A. P. J. Biol. Chem. 271, 15045–15053 (1996).

    Article  CAS  Google Scholar 

  12. Shirke, A. M. & Malinow, R. J. Neurophysiol. 78, 2682–2692 (1997).

    Article  CAS  Google Scholar 

  13. Bortolotto, Z. A. & Collingridge, G. L. Eur. J. Neurosci. 12, 4055–4062 (2000).

    Article  CAS  Google Scholar 

  14. Fukunaga, K. et al. J. Neurochem. 74, 807–817 (2000).

    Article  CAS  Google Scholar 

  15. Drier, E. A. et al. Nat. Neurosci. 5, 316–324 (2002).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported by New York City Council Speaker's Fund for Biomedical Research (D.S.F.L.) and NIMH (L.S.B. and T.C.S.).

Author information

Authors and Affiliations

  1. Departments of Physiology, Pharmacology, and Neurology, SUNY Downstate Medical Center, 450 Clarkson Ave., Brooklyn, 11203, New York, USA

    Douglas S.F. Ling, Larry S. Benardo, Peter A. Serrano, Nancy Blace, Matthew T. Kelly, John F. Crary & Todd C. Sacktor

Authors
  1. Douglas S.F. Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry S. Benardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter A. Serrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nancy Blace
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew T. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John F. Crary
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Todd C. Sacktor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Todd C. Sacktor.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figure 1.

Silver stain of baculovirus/Sf9-expressed PKMζ used in whole-cell recording pipette. Positions of molecular weight standards in kDa are shown on the left. (PDF 287 kb)

Supplementary Figure 2.

No change in input resistance during potentiation by postsynaptic introduction of PKMζ. Upper graph, time course of the individual experiment shown in Fig. 1a and b (each point represents mean ± SEM of 4 consecutive EPSCs). Lower graph, no change in input resistance. (PDF 211 kb)

Supplementary Figure 3.

Postsynaptic introduction of heat-inactivated PKMζ (0 pmol/min/ml phosphotransferase activity) had no effect on evoked EPSCs. (PDF 203 kb)

Supplementary Figure 4.

Evoked EPSCs potentiated by PKMζ were suppressed by 93.0 ± 1.5% with exposure to 10 µM CNQX, a non-NMDA glutamate receptor antagonist (n = 3), indicating that the enhancement is predominantly of AMPAR responses. (PDF 205 kb)

Supplementary Figure 5.

Potentiation of AMPAR responses by PKMζ was not secondary to activation of NMDARs. (a) Enhancement of EPSCs with intracellular introduction of PKMζ in cells voltage-clamped at -75 mV in the presence of 10 µM CPP. (b) Pooled data of the increase in evoked EPSCs by PKMζ in 10 µM CPP (mean ± SEM; n = 6 experiments). Unpaired t-test of PKMζ-mediated EPSC enhancement 12 min after the onset of whole-cell access showed no significant difference between experiments in the presence or absence of CPP. (PDF 210 kb)

Supplementary Figure 6.

PKMζ potentiated spontaneous EPSCs. (a) Examples of spontaneous events recorded 1 and 10 min after initiation of whole-cell recording with 1.4 nM PKMζ in the pipette. The potentiation of sEPSCs by PKMζ was reversed by 1 µM chelerythrine. (b) Mean ± SEM of sEPSC amplitudes (1 min recording, 347 events; 10 min, 379 events; reversal by chelerythrine, 172 events; p < 0.0001, unpaired t-test between 1 and 10 min and no significant difference between 1 min and chelerythrine reversal). PKMζ did not change the frequency of sEPSCs significantly (98.5% ± 3.7 of initial values, n = 4). (PDF 260 kb)

Supplementary Figure 7.

Whole-cell LTP by 4 tetanic trains paired with postsynaptic depolarization to -40 mV. (a) Representative EPSCs pretetanus (recorded at 10 min of establishing whole-cell access, immediately prior to tetanic stimulation) and posttetanus (30 min). (b) Time course of the individual experiment shown in (a). Each point represents mean ± SEM of 4 consecutive EPSCs. Tetanus is at arrow. (PDF 211 kb)

Supplementary Figure 8.

The synaptic potentiation produced by PKMζ occludes LTP. (a) Upper traces, EPSCs at 1 and 10 min after the initiation of whole-cell recording with PKMζ, and posttetanus, at 30 min. No additional potentiation was observed. Lower traces, simultaneously recorded field potentials showed LTP. (b) Time course of individual experiment shown in (a). In whole-cell recordings, tetanization resulted only in PTP. Inset, time course of LTP in simultaneous field recordings. Each point represents mean ± SEM of 4 consecutive EPSCs. (c) Pooled data showing simultaneous LTP in field recordings from experiments presented in Fig. 2b (mean ± SEM; n = 5 experiments). (PDF 242 kb)

Supplementary Figure 9.

Postsynaptic exposure to the dominant negative inhibitor PKMζ-K281W (20 nM) blocked LTP. (a) Silver stain of baculovirus/Sf9-expressed PKMζ-K281W used in the whole-cell recording pipette. (b) Evoked EPSCs recorded 1 and 10 min after introduction of PKMζ-K281W with cells held at -40 mV showed no obvious effect on synaptic responses mediated by AMPA and NMDARs. PKMζ-K281W also had no effect on passive membrane properties (not shown). (c) Upper traces, whole-cell EPSCs pre- and posttetanization, showing no persistent potentiation after exposure to PKMζ-K281W. Lower traces, simultaneously recorded field potentials showed LTP. (d) Time course of the individual experiment shown in (c). Each point represents mean ± SEM of 4 consecutive EPSCs. Tetanization resulted only in PTP. Inset, time course of simultaneous field recording showed LTP. (e) Pooled data showing simultaneous LTP in field recordings from experiments presented in Fig. 2c (mean ± SEM; n = 5 experiments). Whole-cell experiments immediately before and after those with PKMζ-K281W showed normal LTP. (PDF 358 kb)

Supplementary Figure 10.

Persistent phosphorylation by PKMζ is necessary for LTP maintenance. (a) Staurosporine (100 nM in 0.001% DMSO) applied prior to the tetanic stimulation blocked the induction of LTP. Pooled field recording data are mean ± SEM of 4 experiments. (b) Representative field potential traces showing 1 min pretetanus, 1 hr posttetanus (immediately prior to drug application), and 5 hr posttetanus. Above, staurosporine (100 nM in 0.001% DMSO); center, chelerythrine (1 µM in 0.001% DMSO); below, myristoylated ζ-pseudosubstrate peptide (1 µM). For data presented in Fig. 3, one-way ANOVA showed significant differences among DMSO alone, staurosporine, chelerythrine, and ζ-pseudosubstrate peptide, 4 hr post-application [F(3, 14) = 10.11, p = 0.0008]. Post hoc unpaired t-test showed significant differences for both chelerythrine and ζ-pseudosubstrate peptide compared to both DMSO and staurosporine (p < 0.01). No significant differences were observed between DMSO and staurosporine, and between chelerythrine and ζ-pseudosubstrate peptide. Staurosporine effectively inhibited conventional PKCα, novel PKCε, and CaMKII at low nanomolar concentrations, but was ineffective on PKMζ up to 100 nM (n = 3; the SEM, not shown for clarity in Fig. 3, were less than 30% of the means for all data points; p < 0.02, Wilcoxon's independent samples test, PKMζ compared to PKCα, PKCε and CaMKII). Chelerythrine inhibited PKMζ at lower concentrations than that required to inhibit PKCα, PKCε, and CaMKII (n = 3; p < 0.02). The myristoylated ζ-pseudosubstrate peptide selectively inhibited PKMζ relative to CaMKII (n = 3; p < 0.02). (GIF 18 kb)

Supplementary Methods. (PDF 18 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ling, D., Benardo, L., Serrano, P. et al. Protein kinase Mζ is necessary and sufficient for LTP maintenance. Nat Neurosci 5, 295–296 (2002). https://doi.org/10.1038/nn829

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nn829

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing